Derivatives of isoindigo, indigo and indirubin and methods of treating cancer
View Patent ↗A compound called NATURA, which is a derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirubin derivatives are designed such that the bioactivity or bioavailability of the compound is increased. Methods of synthesizing these derivatives is also taught. In addition, pharmaceutical compositions that include a therapeutically effective amount of at least one of these derivatives and a pharmaceutically acceptable carrier. A method for the use of these pharmaceutical compositions and compounds is taught, wherein a therapeutically effective amount is administered to an animal having solid tumor cancer. The pharmaceutical composition or compound can be re-administered to the animal until a desired treatment or result is accomplished.
1. A compound of formula (I), (II), or (III)
wherein R 1 or R 2 is independently an acetylated monosaccharide; and
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , or R 10 is independently a hydrogen, a monosaccharide, a disaccharide, a halogen, a hydrocarbyl group, or a functional hydrocarbyl group substituted with one or more hydroxy moieties, carboxy moieties, nitroxy moieties, monosaccharides, disaccharides, amines, amides, thiols, sulfate, sulfonate, sulfonamide, or halogens, wherein the hydrocarbyl has 1 to 12 carbon atoms.
2. The compound of claim 1 , wherein R 1 or R 2 , is an acetylated arabinose, glucose, mannose, ribose or xylose.
3. A pharmaceutical composition for treatment of cancer in an animal, comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 1 , comprising an additional agent selected from the group consisting of radiotherapeutic agents, hormonal therapy agents, immunotherapeutic agents, chemotherapeutic agents, cryotherapeutic agents and gene therapy agents.
5. The pharmaceutical composition of claim 1 , wherein the compound is formulated for oral administration.
6. A method for treatment of cancer, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 3 to an animal.
7. The method of claim 6 , wherein said animal is a human, and wherein the compound is administered in combination with an additional agent selected from the group consisting of radiotherapeutic agents, hormonal therapy agents, immunotherapeutic agents, chemotherapeutic agents, cryotherapeutic agents and gene therapy agents.
8. A method of synthesizing a meisoindigo compound comprising:
adding about equal molar amounts of 2-hydroxyindole and N-methyl-indolinyl-diketone to produce a reaction substance;
mixing the reaction substance with an excess amount of glacial acetic acid to make a mixture;
heating the mixture to about 70 to 80° C. for 1 to 3 hours to form a precipitate; and
recovering the precipitate as the meisoindigo compound.
9. The method of claim 8 , wherein the precipitate is washed with at least glacial acetic acid, water, or ethanol.
10. A method of treating cancer in an animal, comprising administering to an animal with cancer a therapeutically effective amount of a compound of formula (I), (II), or (III)
wherein R 1 or R 2 is independently an acetylated monosaccharide; and
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , or R 10 is independently a hydrogen, a monosaccharide, a disaccharide, a halogen, a hydrocarbyl group, or a functional hydrocarbyl group substituted with one or more hydroxy moieties, carboxy moieties, nitroxy moieties, monosaccharides, disaccharides, amines, amides, thiols, sulfate, sulfonate, sulfonamide, or halogens, wherein the hydrocarbyl has 1 to 12 carbon atoms.
11. The method of claim 10 , wherein R 1 or R 2 , is an acetylated arabinose, glucose, mannose, ribose or xylose.
12. The method of claim 10 , wherein said animal is a human and the composition is administered orally.
13. The method of claim 10 , wherein the compound is administered in combination with an additional agent selected from the group consisting of radiotherapeutic agents, hormonal therapy agents, immunotherapeutic agents, chemotherapeutic agents, cryotherapeutic agents and gene therapy agents.
14. The method of claim 10 , wherein the solid tumor cancer being treated is colon cancer, hormone dependent or independent prostate cancer, breast cancer, or lung cancer.
15. The method of claim 10 , wherein the solid tumor cancer is hormone dependent or independent prostate cancer.